allergic rhinitis
Conditions
Interventions
Research group:None
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients meet the clinical diagnostic criteria of the latest allergic rhinitis treatment guidelines; 2. Subjects test positive for allergens: allergen-specific IgE or total serum IgE is positive, and allergen skin prick test is positive; 3. Patients with moderate to severe perennial allergic rhinitis whose symptoms cannot be adequately controlled by standardized symptomatic medication; 4. Patients receiving anti-IgE monoclonal antibody therapy and have signed the informed consent for this treatment plan.
Exclusion criteria
Exclusion criteria: 1. Patients allergic to the active ingredient of Omalizumab or other excipients; 2. Patients with acute attacks or acute exacerbation of asthma complicated by allergic rhinitis; 3. Patients at high risk of parasitic infections such as worms; 4. Patients with severe systemic diseases (such as immunodeficiency or malignant tumors); 5. Patients with acute infections; 6. Patients lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale;Total Nasal Symptom Score; | — |
Countries
China
Contacts
Public ContactYuqin Deng
Renmin Hospital of Wuhan University
Outcome results
None listed